Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
1999
Topical Miltefosine for Skin Metastases in Breast Cancer
Sample size: 33
publication
Evidence: moderate
Author Information
Author(s): Terwogt J M M, Mandjes I A M, Sindermann H, Beijnen J H, ten Bokkel Huinink W W
Primary Institution: The Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis
Hypothesis
Topical application of miltefosine can be an effective treatment for skin metastases from breast cancer.
Conclusion
Topical miltefosine is an effective treatment modality in patients with skin metastases from breast cancer.
Supporting Evidence
- The overall response rate was 43% for 30 evaluable patients.
- The treatment resulted in a 23% complete response and a 20% partial response.
- The median response duration was 18 weeks.
Takeaway
Doctors tested a cream with miltefosine on patients with skin cancer from breast cancer, and it helped many of them without causing serious side effects.
Methodology
A phase II study was performed where a 6% miltefosine solution was applied to patients with cutaneous metastases from breast cancer.
Statistical Information
Confidence Interval
8–68 weeks
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website